Skip directly to content

Dutch Apply

DEADLINE FOR APPLICATION

  • Application submission start: Mar 15 2017
  • Application deadline: Jun 1 2017, 24.00 hrs
  • Applications reviewed by commission: July 2017
  • Awards announcement: Sep 2017
  • Research period: Dec 2017 onwards

HOW TO APPLY

Applications are to be submitted to Pfizer through an online submission website. Visit www.europeaspire.org go to the Dutch ASPIRE I-CRP tab and click on “apply”. From there you will be routed to Pfizer’s global investigator-initiated research website. Click on “Submit an IIR Request” and follow the online instructions.
When asked if you are applying for a competitive grant program, select yes. Then, select the appropriate program name from the dropdown list.

  • FULL finalized protocol (summary, objectives, background, methods, references) with a maximum
    of 2000 words excluding references
  • Abbreviated curriculum vitae (CV) (limited to 3 pages)
  • Budget for proposed research
  • Cover letter on institution letterhead
  • 3 of the most relevant articles from the applicant’s scientific publications (if applicable)
  • Description of available laboratory facilities (if applicable)
  • Listing of other research support available with a description of overlap and, if applicable, a listing
    of consenting collaborators (including CV’s)
  • Bibliography of relevant references

APPLICATION PROCESS

No other government, non-governmental, or industry-sponsored projects may cover the same work scope as the grant application to the ASPIRE Program. However, an ASPIRE Program grant may be related to other funding from foundations or government agencies, as long as there is no direct overlap. It is the responsibility of the applicant to justify the novelty of the proposal and provide evidence that the application does not overlap with any current or pending funding. Due to the competitive nature of these awards, Pfizer cannot provide any additional funding support beyond what has been requested and approved by the external independent review panel.

QUESTIONS

Coordinator e-mail address: Jolanda.vanBodegraven@pfizer.com